

## Codering van neuro-endocriene tumoren

Description	ICDO
<i>(Neuro)endocrine microadenoma (&lt; 0,5 cm)</i>	8150/0
<i>(Neuro)endocrine tumour (NET)</i>	
(neuro)endocrine tumour G1 (NET G1) - (well differentiated)	8240/3
carcinoid tumour/carcinoma	8240/3
(neuro)endocrine tumour G2 (NET G2) - (intermediate differentiated)	8249/3
atypical carcinoid	8249/3
non-functional pancreatic (neuro)endocrine tumour NOS (no differentiation in NET G1 or NET G2)	8150/3
<b>NET G3 (rare)</b>	<b>8246/3</b>
<i>(Neuro)endocrine carcinoma (NEC)</i>	
(neuro)endocrine carcinoma (NEC), well differentiated / low grade	8240/3
(neuro)endocrine carcinoma (NEC), intermediate differentiated / <b>G2</b>	8249/3
(neuro)endocrine carcinoma (NEC), poorly differentiated / high grade / <b>G3</b>	<b>8246/3</b>
(neuro)endocrine carcinoma (NEC), NOS ( <b>no grading mentioned</b> )	8246/3
large cell (neuro)endocrine carcinoma (large cell NEC)	8013/3
small cell (neuro)endocrine carcinoma (small cell NEC)	8041/3
<b>Mixed small cell and large cell carcinoma (lung)</b>	<b>8045/3</b>
<b>Goblet cell carcinoid</b>	<b>8243/3</b>
<b>Merkel cell carcinoma</b>	<b>8247/3</b>
<i>Mixed exocrine-(neuro)endocrine carcinoma</i>	
mixed islet cell (endocrine) and exocrine adenocarcinoma of the pancreas	8154/3
mixed acinar-(neuro)endocrine-ductal carcinoma of the pancreas	8154/3
mixed acinar-(neuro)endocrine carcinoma of the pancreas	8154/3
mixed ductal-(neuro)endocrine carcinoma of the pancreas	8154/3
MANEC (Mixed Adeno-Neuroendocrine Carcinoma = mixed carcinoid-adenocarcinoma)*	8244/3
<i>Functional neuroendocrine pancreatic tumour / carcinoma with hormonal syndrome</i>	
Insulin-producing (insulinoma)	8151/3
Glucagon-producing (glucagonoma)	8152/3
Gastrin-producing (gastrinoma) / Zollinger-Ellison	8153/3
VIP-producing (VIPoma)	8155/3
Somatostatin-producing (somatostatinoma)	8156/3
Serotonin producing with carcinoid syndrome	8241/3
Enterochromaffin cell (EC), serotonin producing (neuro)endocrine tumour	8241/3

\* MANEC outside the pancreas (8244/3) : only to be used if > 30% of both components present or if specific terminology used by the pathologist; not to be used for adenocarcinoma with scattered neuroendocrine cells nor for an endocrine neoplasm with a focal non-neuroendocrine component !

■ Correction/adaptation/addition to version feb 2015